Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
October 21 2024 - 7:00AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company
developing transformational treatments for patients with serious
metabolic diseases marked by high unmet medical need, today
announced an upcoming oral presentation and two late-breaking
poster presentations at the 75th Annual American Association for
the Study of Liver Diseases (AASLD) The Liver
Meeting
® 2024 taking place from November 15-19,
2024, in San Diego. The presentations will highlight findings from
the 96-week Phase 2b HARMONY study evaluating the efficacy and
safety of lead product candidate efruxifermin (EFX) in patients
with pre-cirrhotic metabolic dysfunction-associated steatohepatitis
(MASH), fibrosis stage 2 or 3 (F2-F3), along with insights from an
analysis using AI and digital-based pathology.
Details for the presentations are as
follows:
Title: Efruxifermin
Significantly Improved Liver Fibrosis at Week 96 in the HARMONY
Study Across Subgroups and Improvements Were Associated With
Changes in Biomarkers
Presenter: Mazen Noureddin,
M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital
and Director, Houston Research Institute
Date/Time: Sunday, November 17,
2024, from 2:00 PM – 2:15 PM PST
Publication Number: 158
Oral Session: MASLD and MASH –
New Therapies
Title: Efruxifermin
significantly reduced proportion of subjects with at-risk MASH and
led to near-complete histological disease reversal at week 96 in
the HARMONY study
Presenter: Mazen Noureddin,
M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital
and Director, Houston Research Institute
Date/Time: Monday, November 18,
2024, from 8:00 AM – 5:00 PM PST
Publication Number: 5021
Session: Late Breaking
Posters
Title: AI and digital-based
pathology corroborate reduction in fibrosis observed by
conventional pathology with efruxifermin treatment of patients with
F2-F3 MASH in the HARMONY study
Presenter: Mazen Noureddin,
M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital
and Director, Houston Research Institute
Date/Time: Monday, November 18,
2024, from 8:00 AM – 5:00 PM PST
Publication Number: 5047
Session: Late Breaking
Posters
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company
developing transformational treatments for patients with serious
metabolic diseases marked by high unmet medical need, including
MASH. Akero's lead product candidate, EFX, is currently being
evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b
clinical trial in patients with compensated cirrhosis due to MASH
(F4 fibrosis), as well as three ongoing Phase 3 clinical trials in
patients with pre-cirrhotic MASH or compensated cirrhosis due to
MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and
SYNCHRONY Outcomes. The SYNCHRONY program builds on the
results of two Phase 2b clinical trials, the HARMONY study in
patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in
patients with compensated cirrhosis due to MASH (F4) in which
patients have been treated for up to 96 weeks. Akero is
headquartered in South San Francisco. Visit us
at akerotx.com and follow us
on LinkedIn and X for more information.
Investor Contact:Christina
TartagliaPrecision
AQ212.362.1200christina.tartaglia@precisionaq.com
Media Contact:Peg
RusconiDeerfield GroupPeg.rusconi@deerfieldgroup.com
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Dec 2023 to Dec 2024